Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Ad5CMV-p53 gene + unspecified PD-1 antibody |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Ad5CMV-p53 gene | Advexin|INGN-201|RPR/INGN-201|Adeno-p53|Ad-p53 | p53 Gene Therapy 4 | Advexin (Ad5CMV-p53) is a replication-defective adenoviral-CMV vector that encodes a wild-type Tp53 gene, which induces tumor cells to produce wild-type Tp53 to block cell cycle progression (PMID: 19169960). | |
unspecified PD-1 antibody | Experimental PD-1 antibody | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|